Neuroprotective effect of naphtha[1,2-d]thiazol-2-amine in an animal model of Parkinson's disease

References

• P Jenner, CW Olanow. Understanding cell death in Parkinson's disease. Ann Neurol 1998;44:S72–S84.
   PubMed Web of Science ®Google Scholar
• CW Olanow, WG Tatton. Etiology and pathogenesis of Parkinson's disease. Annu Rev Neurosci 1999;22:123–144.
   PubMed Web of Science ®Google Scholar
• BH Juurlink, PG Paterson. Review of oxidative stress in brain and spinal cord injury: Suggestions for pharmacological and nutritional management strategies. J Spinal Cord Med 1998;21:309–334.
   PubMedGoogle Scholar
• RG Shulman, DL Rothman, KL Behar, F Hyder. Energetic basis of brain activity: Implications for neuroimaging. Trends Neurosci 2004;27:489–495.
   PubMed Web of Science ®Google Scholar
• Y Gilgun-Sherki, E Melamed, D Offen. Oxidative stress induced neurodegenerative diseases: The need for antioxidants that penetrate the blood brain barrier. Neuropharmacology 2001;40:957–959.
   Web of Science ®Google Scholar
• N Jha, O Jurma, G Lalli, Y Liu, EH Pettus, JT Greenamyre, RM Liu, HJ Forman, JK Andersen. Glutathione depletion in PC12 results in selective inhibition of mitochondrial complex I activity. Implications for Parkinson's disease. J Biol Chem 2000;275:26096–26101.
   PubMed Web of Science ®Google Scholar
• H Saggu, J Cooksey, D Dexter, FR Wells, A Lees, P Jenner, CD Marsden. A selective increase in particulate superoxide dismutase activity in Parkinsonian substantia nigra. J Neurochem 1989;53:692–697.
   PubMed Web of Science ®Google Scholar
• SJ Kish, C Morito, O Hornykiewicz. Glutathione peroxidase activity in Parkinson's disease brain. Neurosci Lett 1985;58:343–346.
   PubMed Web of Science ®Google Scholar
• JK Andersen. Oxidative stress in neurodegeneration: Cause or consequence?. Nat Med 2004;10 (Suppl):S18–S25.
   PubMed Web of Science ®Google Scholar
• PA LeWitt, DC Taylor. Protection against Parkinson's disease progression: Clinical experience. Neurotherapeutics 2008;5:210–225.
   PubMed Web of Science ®Google Scholar
• TM Dawson, VL Dawson. Neuroprotective and neurorestorative strategies for Parkinson's disease. Nat Neurosci 2002;5:S1058–S1061.
   PubMed Web of Science ®Google Scholar
• JH Jeremiah, V Roubert, C Dolo, C Charnet, B Spinnewyn, S Cornet, A Rolland, JG Marin, D Bigg, PE Chabrier. Phenolic thiazoles as novel orally-active neuroprotective agents. Bioorg Med Chem Lett 2004;14:157–160.
   PubMed Web of Science ®Google Scholar
• M Amir, F Azam. Synthesis and biological evaluation of some 4-thiazolidinones. Indian J Het Chem 2004;14:119–122.
   Web of Science ®Google Scholar
• F Azam, S Singh, SL Khokhra, O Prakash. Synthesis of Schiffs bases of Naphtha[1,2-d]thiazol-2-amine and metal complexes of 2-(2′-Hydroxy)benzylideneaminonaphthothiazole as potential antimicrobial agents. J Zhejiang Univ Sci B 2007;8:446–452.
   PubMedGoogle Scholar
• P Jimonet, F Audiau, M Barreau, JC Blanchard, A Boireau, Y Bour, MA Coleno, A Doble, G Doerflinger, CD Huu, MH Donat, JM Duchesne, P Ganil, C Gueremy, E Honore, B Just, R Kerphirique, S Gontier, P Hubert, PM Laduron, JL Blevec, M Meunier, JM Miquet, C Nemecek, M Pasquet, O Piot, J Pratt, J Rataud, M Reibaud, JM Stutzmann, S Mignani. Riluzole series. Synthesis and in vivo “Antiglutamate” activity of 6-Substituted-2-benzothiazolamines and 3-Substituted-2-imino-benzothiazolines. J Med Chem 1999;42:2828–2843.
   PubMed Web of Science ®Google Scholar
• JJP Bennett, MF Piercey. Pramipexole–a new dopamine agonist for the treatment of Parkinson's disease. J Neurol Sci 1999;163:25–31.
   PubMed Web of Science ®Google Scholar
• B Ferger, P Teismann, J Mierau. The dopamine agonist pramipexole scavenges hydroxyl free radicals induced by striatal application of 6-hydroxydopamine in rats: An in vivo microdialysis study. Brain Res 2000;883:216–223.
   PubMed Web of Science ®Google Scholar
• Y Fujita, Y Izawa, N Ali, Y Kanematsu, K Tsuchiya, S Hamano, T Tamaki, M Yoshizumi. Pramipexole protects against H2O2-induced PC12 cell death. Naunyn Schmiedebergs Arch Pharmacol 2006;372:257–266.
   PubMed Web of Science ®Google Scholar
• MD Ryck, M Verhoye, AMV der Linden. Diffusion-weighted MRI of infarct growth in a rat photochemical stroke model: Effect of lubeluzole. Neuropharmacology 2000;39:691–702.
   PubMed Web of Science ®Google Scholar
• RN Mueller, DJ Deyo, DR Brantley, JF Disterhoft, MH Zornow. Lubeluzole and conditioned learning after cerebral ischemia. Exp Brain Res 2003;152:329–334.
   PubMed Web of Science ®Google Scholar
• K Maiese, M TenBroeke, I Kue. Neuroprotection of lubeluzole is mediated through the signal transduction pathways of nitric oxide. J Neurochem 1997;68:710–714.
   PubMed Web of Science ®Google Scholar
• A Boireau, P Dubedat, F Bordier, A Imperato, S Moussaoui. The protective effect of riluzole in the MPTP model of Parkinson's disease in mice is not due to a decrease in MPP(+) accumulation. Neuropharmacology 2000;39:1016–1020.
   PubMed Web of Science ®Google Scholar
• MC Obinu, M Reibaud, V Blanchard, S Moussaoui, A Imperato. Neuroprotective effect of riluzole in a primate model of Parkinson's disease: Behavioral and histological evidence. Mov Disord 2002;17:13–19.
   PubMed Web of Science ®Google Scholar
• A Storch, K Burkhardt, AC Ludolph, J Schwarz. Protective effects of riluzole on dopamine neurons: Involvement of oxidative stress and cellular energy metabolism. J Neurochem 2000;75:2259–2269.
   PubMed Web of Science ®Google Scholar
• E Bezard, JM Stutzmann, C Imbert, T Boraud, A Boireau, CE Gross. Riluzole delayed appearance of parkinsonian motor abnormalities in a chronic MPTP monkey model. Eur J Pharmacol 1998;356:101–104.
   PubMed Web of Science ®Google Scholar
• F Azam, IA Alkskas, SL Khokra, O Prakash. Synthesis of some novel N4-(naphtha[1,2-d]thiazol-2-yl)semicarbazides as potential anticonvulsants. Eur J Med Chem 2008. In press;doi:10.1016/j.ejmech.2008.02.007
   Google Scholar
• PM Luthra, S Kumar, F Azam. Reduction of haloperidol induced motor impairments in Naphtha[1,2-d]thiazol-2-amine treated mice evocative of its potential as A2A receptor antagonists 2006., International Conference on Targetting Adenosine A2A Receptors in Parkinson's Disease and other CNS disorders. Mass General Hospital, Boston, MA, USA, May 17-19, 2006.
   Google Scholar
• PR Sanberg, R Martinez, RD Shytle, DW Cahill. The catalepsy test: Is a standardized method possible?. In: PR Sanberg, K-P Ossenkoo, M Kavaliers, editors. Motor activity and movement disorders. Totowa, New Jersey: Humana Press; 1996. p 197–211.
   Google Scholar
• H Ohkawa, N Ohishi, K Yagi. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979;95:351–358.
   PubMed Web of Science ®Google Scholar
• J Sedlak, RH Lindsay. Estimation of total, protein-bound and non-protein sulfhydryl groups in tissue with Ellmann's reagent. Anal Biochem 1968;25:192–205.
   PubMed Web of Science ®Google Scholar
• Y Sun, LW Oberley, Y Li. A simple method for clinical assay of superoxide dismutase. Clin Chem 1988;34:497–500.
   PubMed Web of Science ®Google Scholar
• DE Paglia, WN Valentine. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidise. J Lab Clin Med 1967;70:158–170.
   PubMed Web of Science ®Google Scholar
• OH Lowry, NJ Rosenbrough, AL Farr, RJ Randall. Protein measurement with the folin phenol reagent. J Biol Chem 1951;193:265–275.
   PubMed Web of Science ®Google Scholar
• PR Sanberg, M Giordano, MD Bunsey, AB Norman. The catalepsy test: Its ups and downs. Behav Neurosci 1988;102:748–759.
   PubMed Web of Science ®Google Scholar
• ST Frank, WJ Schmidt. Burst activity of spiny projection neurons in the striatum encodes superimposed muscle tetani in cataleptic rats. Exp Brain Res 2003;152:519–522.
   PubMed Web of Science ®Google Scholar
• W Hauber, P Neuscheler, J Nagel, CE Muller. Catalepsy induced by a blockade of dopamine D1 or D2 receptors was reversed by a concomitant blockade of adenosine A2A receptors in the caudate putamen of rats. Eur J Neurosci 2001;14:1287–1293.
   PubMed Web of Science ®Google Scholar
• J Wardas, J Konieczny, E Lorenc-Koci. SCH 58261, an A(2A) adenosine receptor antagonist, counteracts parkinsonian-like muscle rigidity in rats. Synapse 2001;41:160–171.
   PubMed Web of Science ®Google Scholar
• M Correa, A Wisniecki, A Betz, DR Dobson, MF O'Neill, MJ O'Neill, JD Salamone. The adenosine A2A antagonist KF 17837 reverses the locomotor suppression and tremulous jaw movements induced by haloperidol in rats: Possible relevance to parkinsonism. Behav Brain Res 2004;148:47–54.
   PubMed Web of Science ®Google Scholar
• P Jenner, CW Olanow. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology 1996;47:S161–S170.
   PubMed Web of Science ®Google Scholar
• JA Serra, RO Domínguez, ES de Lustig, EM Guareschi, AL Famulari, EL Bartolomé, ER Marschoff. Parkinson's disease is associated with oxidative stress: Comparison of peripheral antioxidant profiles in living Parkinson's Alzheimer's and vascular dementia patients. J Neural Transm 2001;108:1135–1148.
   PubMed Web of Science ®Google Scholar
• BR Shivkumar, V Ravindranath. Oxidative stress and thiol modification induced by chronic administration of haloperidol. J Pharmacol Exp Ther 1993;265:1137–1141.
   PubMed Web of Science ®Google Scholar
• JL Cadet, JB Lohr, DV Jeste. Free radicals and tardive dyskinesia. Trends Neuosci 1986;9:107–108.
   Web of Science ®Google Scholar
• BR Shivkumar, V Ravindranath. Oxidative stress Induced by administration of the neuroleptic drug haloperidol is attenuated by higher doses of haloperidol. Brain Res 1992;595:256–262.
   PubMed Web of Science ®Google Scholar
• BJ Vilner, WD Bowen. Sigma receptor-active neuroleptics are cytotoxic to C6 glioma cells in culture. Eur J Pharmacol 1993;244:199–201.
   PubMed Web of Science ®Google Scholar
• C Behl, F Lezoulac'h, M Widmann, R Rupprecht, F Holsboer. Oxidative stress-resistant cells are protected against haloperidol toxicity. Brain Res 1996;717:193–195.
   PubMed Web of Science ®Google Scholar
• F Lezoualc'h, R Rupprecht, F Holsboer, C Behl. Bcl-2 prevents hippocampal cell death induced by the neuroleptic drug haloperidol. Brain Res 1996;738:176–179.
   PubMed Web of Science ®Google Scholar
• M Polydoro, N Schröder, M Noemia, M Lima, F Caldana, DC Laranja, E Bromberg, R Roesler, J Quevedo, J Cláudio, F Moreira, F Dal-Pizzol. Haloperidol and clozapine induced oxidative stress in the rat brain. Pharmacol Biochem Behav 2004;78:751–766.
   PubMed Web of Science ®Google Scholar
• M Gerlach, D Ben-Schacar, P Riederer, MBH Youdim. Altered brain metabolism of iron as a cause of neurodegenerative diseases?. J Neurochem 1994;63:793–807.
   PubMed Web of Science ®Google Scholar
• AA Horton, S Fairhurst. Lipid peroxidation and mechanisms of toxicity. CRC Crit Rev Toxicol 1987;18:27–79.
   Web of Science ®Google Scholar
• SK Jain. The accumulation of malonyldialdehyde, a product of fatty acid peroxidation, can disturb aminophospholipid organization in the membrane bilayer of human erythrocytes. J Biol Chem 1984;25:3391–3394.
   Google Scholar
• DT Dexter, CJ Carter, FR Wells, F Javoy-Agid, Y Agid, A Lees, P Jenner, CD Marsden. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 1989;52:381–389.
   PubMed Web of Science ®Google Scholar
• JT Coyle, P Puttfarcken. Oxidative stress, glutamate, and neurodegenerative disorders. Science 1993;262:689–695.
   PubMed Web of Science ®Google Scholar
• JM McCord, ED Day. Superoxide dependent production of hydroxyl radical catalyzed by iron-EDTA complex. FEBS Lett 1978;86:139–142.
   PubMed Web of Science ®Google Scholar
• KR Maddipati, LJ Marnett. Characterization of the major hydroperoxide-reducing activity of human plasma. Purification and properties of a selenium-dependent glutathione peroxidise. J Biol Chem 1987;262:17398–17403.
   PubMed Web of Science ®Google Scholar
• G Vendemiale, I Grattagliano, E Altomare. An update on the role of free radicals and antioxidant defense in human disease. Int J Clin Lab Res 1999;29:49–55.
   PubMedGoogle Scholar
• V Parikh, MM Khan, SP Mahadik. Differential effects of antipsychotics on expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. J Psychiatr Res 2003;37:43–51.
   PubMed Web of Science ®Google Scholar
• A Singh, PS Naidu, SK Kulkarni. Possible antioxidant and neuroprotective mechanism of FK506 in attenuating haloperidol-induced orofacial dyskinesia. Eur J Pharmacol 2003;477:87–94.
   PubMed Web of Science ®Google Scholar
• M Vairetti, A Battaglia, N Carfagna, PL Canonico, F Berte, P Richelmi. Antioxidant properties of MDL and MMDL, two nicergoline metabolites, during chronic administration of haloperidol. Eur J Pharmacol 2002;453:69–73.
   PubMed Web of Science ®Google Scholar
• S Balijepalli, RS Kenchappa, MR Boyd, V Ravindranath. Protein thiol oxidation by haloperidol results in inhibition of mitochondrial complex I in brain regions: Comparison with atypical antipsychotics. Neurochem Int 2001;38:425–435.
   PubMed Web of Science ®Google Scholar
• AM Elkashef, RJ Wyatt. Tardive dyskinesia: Possible involvement of free radical and treatment with vitamin E. Schizophr Bull 1999;25:731–740.
   PubMed Web of Science ®Google Scholar
• PS Naidu, A Singh, SK Kulkarni. Carvedilol attenuates neuroleptic-induced orofacial dyskinesia: Possible antioxidant mechanisms. Br J Pharmacol 2002;136:193–200.
   PubMed Web of Science ®Google Scholar
• R Reddy, SP Mahadik, S Mukherjee, T Makar. Neuroleptic effects on the enzymes of the antioxidant defense system in manic and schizophrenic patients. Biol Psychiatry 1992;31 (Suppl. 1):248.
   Google Scholar
• R Reddy, H Kelkar, SP Mahadik, S Mukherjee. Abnormal erythrocyte catalase activity in schizophrenic patients. Schizophr Res 1993;9:227.
   Google Scholar
• AS Perumal, VB Gopal, WK Tordzro, TB Cooper, JL Cadet. Vitamin E attenuates the toxic effects of 6-hydroxydopamine on free radical scavenging systems in rat brain. Brain Res Bull 1992;29:699–701.
   PubMed Web of Science ®Google Scholar
• KS Zafar, I Sayeed, A Siddiqui, M Ahmad, S Salim, F Slam. Dose-dependent protective effect of selenium in partial lesion model of Parkinson's disease: Neurobehavioral and neurochemical evidences. J Neurochem 2003;84:438–446.
   PubMed Web of Science ®Google Scholar
• M Ahmad, S Saleem, AS Ahmad, S Yousuf, MA Ansari, MB Khan, T Ishrat, RK Chaturvedi, AK Agarwal, F Islam. Ginkgo biloba affords dose-dependent protection against 6-hydroxydopamine-induced parkinsonism in rats: Neurobehavioural, neurochemical and immunohistochemical evidences. J Neurochem 2005;93 (1):94–104.
   PubMed Web of Science ®Google Scholar